Aptose Biosciences Inc. (NASDAQ:APTO) shares shot up 5.8% during mid-day trading on Friday . The stock traded as high as $2.20 and last traded at $2.20, with a volume of 52,729 shares. The stock had previously closed at $2.08.

Several brokerages have issued reports on APTO. Zacks Investment Research lowered Aptose Biosciences from a “hold” rating to a “sell” rating in a report on Monday, July 11th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, June 9th. Royal Bank Of Canada reissued an “outperform” rating and issued a $23.00 price objective on shares of Aptose Biosciences in a research note on Monday, June 13th. Roth Capital raised Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $4.00 to $8.00 in a research note on Monday, June 13th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research note on Thursday, June 9th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Aptose Biosciences presently has a consensus rating of “Buy” and a consensus price target of $12.30.

The firm’s market capitalization is $28.36 million. The company’s 50 day moving average price is $2.40 and its 200 day moving average price is $2.59.

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.